Morgan Stanley analyst Thibault Boutherin raised the firm’s price target on Novartis (NVS) to $170 from $143 and keeps an Overweight rating on the shares. The firm came away from its deep dive into nine pipeline assets seeing $23B of risk-adjusted potential and an additional $13B upside in a 100% success scenario, the analyst tells investors. While the firm acknowledges risks, it believes that “the risk/reward remains to the upside, in particular on remibrutinib,” the analyst added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis: Late-Stage Pipeline and Pelacarsen Upside Support Buy Rating Despite Patent Headwinds
- Novartis: Strengthened Growth Outlook and Undervalued Late‑Stage Pipeline Support Buy Rating and Higher Target Price
- Merck’s offer for Terns leaves room for another bidder, says William Blair
- Clear Street says Merck’s bet on TERN-701 sharpens investment case for ELVN-001
- Shareholders Sue Mereo BioPharma (MREO) Over Brittle Bone Drug Claims